Literature DB >> 26364181

Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.

Francesca Piludu1, Simona Marzi2, Andrea Pace3, Veronica Villani3, Alessandra Fabi4, Carmine Maria Carapella5, Irene Terrenato6, Anna Antenucci7, Antonello Vidiri1.   

Abstract

INTRODUCTION: The aim of this study is to investigate whether early changes in tumor volume and perfusion measurements derived from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) may predict response to antiangiogenic therapy in recurrent high-grade gliomas.
METHODS: Twenty-seven patients who received bevacizumab every 3 weeks were enrolled in the study. For each patient, three MRI scans were performed: at baseline, after the first dose, and after the fourth dose of bevacizumab. The entire tumor volume (V(tot)), as well as contrast-enhanced and noncontrast-enhanced tumor subvolumes (V(CE-T1) and V(NON-CE-T1), respectively) were outlined using post-contrast T1-weighted images as a guide for the tumor location. Histogram analysis of normalized IAUGC (nIAUGC) and transfer constant K(trans) maps were performed. Each patient was classified as a responder patient if he/she had a partial response or a stable disease or as a nonresponder patient if he/she had progressive disease.
RESULTS: Responding patients showed a larger reduction in V(NON-CE-T1) after a single dose, compared to nonresponding patients. Tumor subvolumes with increased values of nIAUGC and K(trans), after a single dose, significantly differed between responders and nonresponders. The radiological response was found to be significantly associated to the clinical outcome. After a single dose, V(tot) was predictive of overall survival (OS), while V(CE-T1) showed a tendency of correlation with OS.
CONCLUSION: Tumor subvolumes with increased nIAUGC and K(trans) showed the potential for improving the diagnostic accuracy of DCE. Early assessments of the entire tumor volume, including necrotic areas, may provide complementary information of tumor behavior in response to anti-VEGF therapies and is worth further investigation.

Entities:  

Keywords:  Bevacizumab; DCE MRI; High-grade glioma; Perfusion MRI; Quantitative image analysis

Mesh:

Substances:

Year:  2015        PMID: 26364181     DOI: 10.1007/s00234-015-1582-9

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  38 in total

Review 1.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.

Authors:  James P B O'Connor; Alan Jackson; Geoff J M Parker; Caleb Roberts; Gordon C Jayson
Journal:  Nat Rev Clin Oncol       Date:  2012-02-14       Impact factor: 66.675

2.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

3.  MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.

Authors:  Shahrzad Jalali; Caroline Chung; Warren Foltz; Kelly Burrell; Sanjay Singh; Richard Hill; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2014-04-23       Impact factor: 12.300

4.  Reducing intratumour acute hypoxia through bevacizumab treatment, referring to the response of quiescent tumour cells and metastatic potential.

Authors:  S Masunaga; Y Liu; H Tanaka; Y Sakurai; M Suzuki; N Kondo; A Maruhashi; K Ono
Journal:  Br J Radiol       Date:  2011-05-17       Impact factor: 3.039

5.  Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging--pilot study.

Authors:  Rahul N Sawlani; Jeffrey Raizer; Sandra W Horowitz; Wanyong Shin; Sean A Grimm; James P Chandler; Robert Levy; Christopher Getch; Timothy J Carroll
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

6.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

7.  Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.

Authors:  J J C Verhoeff; C Lavini; M E van Linde; L J A Stalpers; C B L M Majoie; J C Reijneveld; W R van Furth; D J Richel
Journal:  Ann Oncol       Date:  2010-01-11       Impact factor: 32.976

8.  Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.

Authors:  B M Ellingson; S Sahebjam; H J Kim; W B Pope; R J Harris; D C Woodworth; A Lai; P L Nghiemphu; W P Mason; T F Cloughesy
Journal:  AJNR Am J Neuroradiol       Date:  2013-10-17       Impact factor: 3.825

Review 9.  Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols.

Authors:  P S Tofts; G Brix; D L Buckley; J L Evelhoch; E Henderson; M V Knopp; H B Larsson; T Y Lee; N A Mayr; G J Parker; R E Port; J Taylor; R M Weisskoff
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

10.  Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Authors:  V Vaccaro; A Fabi; A Vidiri; D Giannarelli; G Metro; S Telera; S Vari; F Piludu; M A Carosi; V Villani; F Cognetti; A Pompili; L Marucci; C M Carapella; A Pace
Journal:  Biomed Res Int       Date:  2014-05-04       Impact factor: 3.411

View more
  15 in total

Review 1.  New Directions in Anti-Angiogenic Therapy for Glioblastoma.

Authors:  Nancy Wang; Rakesh K Jain; Tracy T Batchelor
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 2.  Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.

Authors:  Alessandra Fabi; Antonello Vidiri
Journal:  Transl Lung Cancer Res       Date:  2016-12

3.  Imaging biomarkers from multiparametric magnetic resonance imaging are associated with survival outcomes in patients with brain metastases from breast cancer.

Authors:  Bang-Bin Chen; Yen-Shen Lu; Chih-Wei Yu; Ching-Hung Lin; Tom Wei-Wu Chen; Shwu-Yuan Wei; Ann-Lii Cheng; Tiffany Ting-Fang Shih
Journal:  Eur Radiol       Date:  2018-05-16       Impact factor: 5.315

4.  Repeatability of dynamic contrast enhanced vp parameter in healthy subjects and patients with brain tumors.

Authors:  Moran Artzi; Gilad Liberman; Deborah T Blumenthal; Felix Bokstein; Orna Aizenstein; Dafna Ben Bashat
Journal:  J Neurooncol       Date:  2018-11-03       Impact factor: 4.130

5.  Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software.

Authors:  Gian Marco Conte; Antonella Castellano; Luisa Altabella; Antonella Iadanza; Marcello Cadioli; Andrea Falini; Nicoletta Anzalone
Journal:  Radiol Med       Date:  2017-01-09       Impact factor: 3.469

6.  Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer.

Authors:  Grégory Kuchcinski; Emilie Le Rhun; Alexis B Cortot; Elodie Drumez; Romain Duhal; Maxime Lalisse; Julien Dumont; Renaud Lopes; Jean-Pierre Pruvo; Xavier Leclerc; Christine Delmaire
Journal:  Eur Radiol       Date:  2017-02-16       Impact factor: 5.315

7.  Dynamic contrast-enhanced MRI may be helpful to predict response and prognosis after bevacizumab treatment in patients with recurrent high-grade glioma: comparison with diffusion tensor and dynamic susceptibility contrast imaging.

Authors:  Yae Won Park; Sung Soo Ahn; Ju Hyung Moon; Eui Hyun Kim; Seok-Gu Kang; Jong Hee Chang; Se Hoon Kim; Seung-Koo Lee
Journal:  Neuroradiology       Date:  2021-03-23       Impact factor: 2.804

8.  Demonstration of DCE-MRI as an early pharmacodynamic biomarker of response to VEGF Trap in glioblastoma.

Authors:  Allison F O'Neill; Lei Qin; Patrick Y Wen; John F de Groot; Annick D Van den Abbeele; Jeffrey T Yap
Journal:  J Neurooncol       Date:  2016-08-30       Impact factor: 4.130

Review 9.  Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics.

Authors:  Jurgita Usinskiene; Agne Ulyte; Atle Bjørnerud; Jonas Venius; Vasileios K Katsaros; Ryte Rynkeviciene; Simona Letautiene; Darius Norkus; Kestutis Suziedelis; Saulius Rocka; Andrius Usinskas; Eduardas Aleknavicius
Journal:  Neuroradiology       Date:  2016-01-15       Impact factor: 2.804

10.  Non-parametric intravoxel incoherent motion analysis in patients with intracranial lesions: Test-retest reliability and correlation with arterial spin labeling.

Authors:  Sonja Stieb; Andreas Boss; Moritz C Wurnig; Pinar S Özbay; Tobias Weiss; Matthias Guckenberger; Oliver Riesterer; Cristina Rossi
Journal:  Neuroimage Clin       Date:  2016-06-02       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.